BMS could soon face competition in the HCM space as Cytokinetics awaits a marketing application decision from the FDA for ...

Bristol Myers Squibb’s examination into whether its heart med Camzyos can spark improvements in patients with non-obstructive ...

J&J also raised its full-year revenue guidance to include sales of the psychiatric drug Caplyta, which the company got from ...

Aficamten, a cardiac myosin inhibitor (CMI), is the cornerstone of Cytokinetics’ near-term prospects. The drug has shown promising results in clinical trials, demonstrating significant gradient ...

Camzyos’ failure in a form of hypertrophic cardiomyopathy dampened its commercial outlook and spurred debate as to whether ...

H.C. Wainwright reiterates Cytokinetics (CYTK) as a top pick after Bristol-Myers (BMY) announced that the Phase 3 ODYSSEY-HCM clinical trial ...

Aficamten, a cardiac myosin inhibitor (CMI), is the cornerstone of Cytokinetics’ near-term prospects. The drug has shown promising results in clinical trials, demonstrating significant gradient ...

Bristol Myers' Camzyos missed goals in a Phase 3 nHCM trial, showing no significant benefits over placebo but raised no new ...

Shares of Bristol-Myers Squibb Company (NYSE: BMY) edged down 0.6% in premarket trading after announcing its Phase 3 ODYSSEY-HCM trial did not meet its primary endpoints. The study evaluated Camzyos ...

The result is a major disappointment for BMS as it effectively cuts the potential market for Camzyos in half. Sales of the ...

Bristol Myers phase III study evaluating Camzyos for the treatment of adult patients with non-obstructive hypertrophic cardiomyopathy fails to meet its dual-primary endpoints.